V. V. Babak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. V. Babak has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Valentinovna Beketova
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic University
9 shared publications - M. D. Suprun
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - M. F. Beketova
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - N. O. Levina
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation
3 shared publications - I. V. Rozanova
Central Clinical Hospital with Polyclinic of the Administrative Directorate of the President of the Russian Federation
2 shared publications - I. Yu. Popov
V.A. Nasonova Research Institute of Rheumatology
2 shared publications
Latest Publications
- Open Access
- 2 March 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (1) , 86-94
The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis
Background. The assessment of organ damage in patients with systemic sclerosis (SSc) is challenging. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) proposed in 2019 has not been sufficiently studied and requires testing for wider use.The aim of the study was to examine the progression of organ damage in patients with systemic sclerosis assessed by SCTC-DI during a one-year prospective follow-up.Materials and methods. A prospective observational study was performed, within the framework of which the SCTC-DI was assessed twice with an interval of 12 [10; 14] months in 74 adult patients (62 (84%) women) with SSc with an average age of 48±13 years. SSc was classified according to the criteria of progressive systemic sclerosis and in 43 (58%) cases was represented by a limited form. The duration of the disease was 92 [47; 164] months. The inclusion criterion was SCTC-DI≥1 point for at least one of 23 indicators at one of the assessment points. Statistical data processing was performed using parametric and nonparametric analysis methods.Results of the study. At inclusion in the study, the median (Me) of the SCTC-DI was 7.5 [4; 12] points (min–max: 0–23). 27 (36%) patients initially had a low degree of damage (SCTC-DI≤5), the rest had moderate or severe damage. Upon repeated assessment, the Me of SCTC-DI decreased to 7 [4; 10] points (min–max: 0–17; p=0.023). After one year, there was a significant decrease in the incidence of digital ulcers, clinical signs of esophageal hypotension and symptoms of gastroesophageal reflux disease (GERD). At the same time, the incidence of myocardial disease associated with SSc increased (ppp=0.027). The decrease in the total SCTC-DI score was statistically associated with the use of oral glucocorticoid therapy during the study period (p=0.011), as well as cyclophosphamide anamnesis (p=0.015).Conclusion. The SCTC-DI was proposed for an objective assessment of changes in the condition of patients with SSc and takes into account irreversible changes in the main manifestations of the disease, which is reflected in an increase in the index value over time. In this study, the total SCTC-DI slightly but reliably increased with a multidirectional change in the values of individual index components. The use of the DI revealed certain of its shortcomings, which impose significant restrictions on its use in practice and mean the need for further work on validating the DI and more precise definitions of the main indicators of irreversible damage.
- 2 March 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (1) , 86-94
Open AccessThe use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis
Background. The assessment of organ damage in patients with systemic sclerosis (SSc) is challenging. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) proposed in 2019 has not been sufficiently studied and requires testing for wider use.The aim of the study was to examine the progression of organ damage in patients with systemic sclerosis assessed by SCTC-DI during a one-year prospective follow-up.Materials and methods. A prospective observational study was performed, within the framework of which the SCTC-DI was assessed twice with an interval of 12 [10; 14] months in 74 adult patients (62 (84%) women) with SSc with an average age of 48±13 years. SSc was classified according to the criteria of progressive systemic sclerosis and in 43 (58%) cases was represented by a limited form. The duration of the disease was 92 [47; 164] months. The inclusion criterion was SCTC-DI≥1 point for at least one of 23 indicators at one of the assessment points. Statistical data processing was performed using parametric and nonparametric analysis methods.Results of the study. At inclusion in the study, the median (Me) of the SCTC-DI was 7.5 [4; 12] points (min–max: 0–23). 27 (36%) patients initially had a low degree of damage (SCTC-DI≤5), the rest had moderate or severe damage. Upon repeated assessment, the Me of SCTC-DI decreased to 7 [4; 10] points (min–max: 0–17; p=0.023). After one year, there was a significant decrease in the incidence of digital ulcers, clinical signs of esophageal hypotension and symptoms of gastroesophageal reflux disease (GERD). At the same time, the incidence of myocardial disease associated with SSc increased (ppp=0.027). The decrease in the total SCTC-DI score was statistically associated with the use of oral glucocorticoid therapy during the study period (p=0.011), as well as cyclophosphamide anamnesis (p=0.015).Conclusion. The SCTC-DI was proposed for an objective assessment of changes in the condition of patients with SSc and takes into account irreversible changes in the main manifestations of the disease, which is reflected in an increase in the index value over time. In this study, the total SCTC-DI slightly but reliably increased with a multidirectional change in the values of individual index components. The use of the DI revealed certain of its shortcomings, which impose significant restrictions on its use in practice and mean the need for further work on validating the DI and more precise definitions of the main indicators of irreversible damage.
- Open Access
- 31 October 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 465-473
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, in particular those receiving anti-B cell therapy with rituximab (RTX), the post-vaccination effect may be insufficient. Since 2022 the long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for COVID-19.The aim of the study is to evaluate the effectiveness of tixagevimab and cilgavimab (TC) for pre-exposure prophylaxis of COVID-19 and its safety in RTX treated patients with AAV.Materials and methods. The prospective study included 63 patients with AAV receiving RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March 2022 to June 2023, TC was administered in a total dose of 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 and in April 2024 a telephone and/or online survey was conducted simultaneously to identify confirmed cases of COVID-19 and adverse reactions. The survey also included the Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering the duration of the TC effect (6 months), COVID-19 cases were divided into two groups depending on the interval after the last administration of the TC: up to 6 months inclusive – group 1; more than 6 months – group 2.Results. During the two-year follow-up period, confirmed COVID-19 was detected in 31.7% patients, the median interval between the last TC administration and the development of COVID-19 was 5.5 [2–19] months. In group 1, which included 12 cases of COVID-19, 92% of patients had a mild form of the disease, only one had lung damage, and there were no fatal outcomes. In group 2, COVID-19, detected after the cessation of the TC effect in 9 patients, was accompanied by lung damage in 89% of cases, required hospitalization in 78%, and fatal in two patients. Four patients had a prolonged course of severe COVID-19 with persistence of SARS-CoV-2 (pCOVID, persistent COVID). In 4 cases, including 3 cases with pCOVID, treatment was carried out with the combined antiviral drug nirmarelvir + ritonavir (Skyvira) in combination with intravenous human immunoglobulin (IVIG) with effect. There were no statistically significant differences in the incidence of COVID-19 in patients with secondary immunodeficiency and without it (p=0.868). At the final stage of the study, the serum level of IgG antibodies to SARS-CoV-2 was examined in 34 patients, its median was 70.4 (0.33–1086.1) binding antibody units (BAU), which indicates a lack of neutralizing antibodies in most patients; there were no statistical differences in their level between patients with and without COVID-19 (p=0.685). No adverse reactions directly related to the use of TC were observed. A high level of the TSQM-9 global treatment satisfaction domain was noted with a median 71.4 (14.3–100); 72,4% of respondents answered “satisfied”– “extremely satisfied” to the first question of TSQM-9 (effectiveness domain).Conclusions. Pre-exposure prophylaxis of COVID-19 using TC in patients with AAV receiving RTM was safe and allowed to reduce the risk of severe COVID-19 and avoid deaths during the period of TC action. After the cessation of TC, an increase in the frequency of severe COVID-19 with the need for hospitalization and deaths was observed, cases of pCOVID were noted. The use of a combination of Skyvira and IVIG for the treatment of pCOVID was effective in all cases. The use of MAB for pre-exposure prophylaxis of COVID-19 in patients with AAV and other rheumatic diseases requires further in-depth study.
- 31 October 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 465-473
Open AccessPre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, in particular those receiving anti-B cell therapy with rituximab (RTX), the post-vaccination effect may be insufficient. Since 2022 the long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for COVID-19.The aim of the study is to evaluate the effectiveness of tixagevimab and cilgavimab (TC) for pre-exposure prophylaxis of COVID-19 and its safety in RTX treated patients with AAV.Materials and methods. The prospective study included 63 patients with AAV receiving RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March 2022 to June 2023, TC was administered in a total dose of 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 and in April 2024 a telephone and/or online survey was conducted simultaneously to identify confirmed cases of COVID-19 and adverse reactions. The survey also included the Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering the duration of the TC effect (6 months), COVID-19 cases were divided into two groups depending on the interval after the last administration of the TC: up to 6 months inclusive – group 1; more than 6 months – group 2.Results. During the two-year follow-up period, confirmed COVID-19 was detected in 31.7% patients, the median interval between the last TC administration and the development of COVID-19 was 5.5 [2–19] months. In group 1, which included 12 cases of COVID-19, 92% of patients had a mild form of the disease, only one had lung damage, and there were no fatal outcomes. In group 2, COVID-19, detected after the cessation of the TC effect in 9 patients, was accompanied by lung damage in 89% of cases, required hospitalization in 78%, and fatal in two patients. Four patients had a prolonged course of severe COVID-19 with persistence of SARS-CoV-2 (pCOVID, persistent COVID). In 4 cases, including 3 cases with pCOVID, treatment was carried out with the combined antiviral drug nirmarelvir + ritonavir (Skyvira) in combination with intravenous human immunoglobulin (IVIG) with effect. There were no statistically significant differences in the incidence of COVID-19 in patients with secondary immunodeficiency and without it (p=0.868). At the final stage of the study, the serum level of IgG antibodies to SARS-CoV-2 was examined in 34 patients, its median was 70.4 (0.33–1086.1) binding antibody units (BAU), which indicates a lack of neutralizing antibodies in most patients; there were no statistical differences in their level between patients with and without COVID-19 (p=0.685). No adverse reactions directly related to the use of TC were observed. A high level of the TSQM-9 global treatment satisfaction domain was noted with a median 71.4 (14.3–100); 72,4% of respondents answered “satisfied”– “extremely satisfied” to the first question of TSQM-9 (effectiveness domain).Conclusions. Pre-exposure prophylaxis of COVID-19 using TC in patients with AAV receiving RTM was safe and allowed to reduce the risk of severe COVID-19 and avoid deaths during the period of TC action. After the cessation of TC, an increase in the frequency of severe COVID-19 with the need for hospitalization and deaths was observed, cases of pCOVID were noted. The use of a combination of Skyvira and IVIG for the treatment of pCOVID was effective in all cases. The use of MAB for pre-exposure prophylaxis of COVID-19 in patients with AAV and other rheumatic diseases requires further in-depth study.
- Open Access
- 28 April 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (2) , 158-164
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.
- 28 April 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (2) , 158-164
Open AccessExperience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.
- Open Access
- 6 September 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (4) , 420-426
Avascular necrosis as a part of post-COVID syndrome. Case reports
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.
- 6 September 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (4) , 420-426
Open AccessAvascular necrosis as a part of post-COVID syndrome. Case reports
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.
- Open Access
- 7 July 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (2) , 452-457
Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distress syndrome. The highest risk of severe traction and death is known to occur in the immunosuppressive group of patients. These patients include rheumatologically patients. Currently, there is no complete understanding of the pathogenesis of the development of covid-19, as well as the pathogenesis of the development of autoimmune diseases. In a pandemic, the question of how the coronavirus infection proceeds in patients on immunosuppressive therapy, in particular on anti-B cell, is relevant. In our case report presents a 69-year-old female with ANCA-associated vasculitis remission having received a B-cell-depleting therapy with rituximab (RTX), who had an ocular lesion as a clinical manifestation of Coronavirus disease 2019 (COVID-19). Two months after RTX treatment, COVID-19 was diagnosed. The patient had extrapulmonary manifestations including central nervous system involvement and ocular symptoms such as conjunctivitis, without respiratory pathology. In this clinical observation, the patient’s disease manifested itself with right-sided conjunctivitis, which is a rare manifestation as the first symptom. This article describes the features of the course and outcome of the disease, as well as, the protective effect of RTX in course of COVID-19 is discussed. A comparative analysis of cases of COVID-19 with eye damage is being carried out. This clinical observation is of great value for doctors of all specialties, especially ophthalmologists. A multidisciplinary approach is crucial to manage COVID-19.
- 7 July 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (2) , 452-457
Open AccessOcular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distress syndrome. The highest risk of severe traction and death is known to occur in the immunosuppressive group of patients. These patients include rheumatologically patients. Currently, there is no complete understanding of the pathogenesis of the development of covid-19, as well as the pathogenesis of the development of autoimmune diseases. In a pandemic, the question of how the coronavirus infection proceeds in patients on immunosuppressive therapy, in particular on anti-B cell, is relevant. In our case report presents a 69-year-old female with ANCA-associated vasculitis remission having received a B-cell-depleting therapy with rituximab (RTX), who had an ocular lesion as a clinical manifestation of Coronavirus disease 2019 (COVID-19). Two months after RTX treatment, COVID-19 was diagnosed. The patient had extrapulmonary manifestations including central nervous system involvement and ocular symptoms such as conjunctivitis, without respiratory pathology. In this clinical observation, the patient’s disease manifested itself with right-sided conjunctivitis, which is a rare manifestation as the first symptom. This article describes the features of the course and outcome of the disease, as well as, the protective effect of RTX in course of COVID-19 is discussed. A comparative analysis of cases of COVID-19 with eye damage is being carried out. This clinical observation is of great value for doctors of all specialties, especially ophthalmologists. A multidisciplinary approach is crucial to manage COVID-19.
- Open Access
- 19 June 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (3) , 37-41
Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis
In the last decade, anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (SV) has been treated with the anti-B-cell drug, rituximab (RTM) both for induction and maintenance therapy. One of the problems of the treatment with RTM in patients with ANCA-SV is the risk of late-onset neutropenia (LON), mechanisms of development of which have not been studied enough yet.Objective: to evaluate the incidence and outcomes of LON in patients with ANCA-SV treated with RTM. Patients and methods. A retrospective analysis of the register of 140 patients with ANCA-SV who received RTM treatment at the V.A. Nasonova Research Institute of Rheumatology from 2009 to 2021 years. The median duration of RTM treatment was 49 (6–121) months, the median of the total RTM dose was 3.5 (0.5–9.5) grams. The duration of follow-up exceeded 6 months after the first administration of RTM.Results and discussion. LON was detected in 16 (11.4%) patients, of which 6 suffered from Wegener's granulomatosis with polyangiitis (GPA), 4 – microscopic polyangiitis (MPA), 4 – Churg-Strauss eosinophilic granulomatosis with polyangiitis (EGPA) and 2 – undifferentiated ANCA-SV. In 8 (50%) out of 16 patients, LON developed within 2 months after the 1st course of RTM, in the remaining 8 patients, on average, after 10 (4– 15.5) months. A lethal outcome was documented in 5 (31.2%) of 16 cases of LON (1 with MPA, 3 with GPA, and 1 with EGPA) on average 2 (1.5–9) months after the 1st course of RTM, at the same time, in 4 patients LON was complicated by pneumonia, including 2 with septic shock, in another 1 case LON was combined with the development of acute myocardial infarction and progression of chronic renal failure. Overall mortality among 140 patients with ANCA-SV treated with RTM was 11.4%, while in cases with a fatal outcome, the frequency of LON reached 31.2%.Conclusion. Thus, LON induced by RTM is a common (11%) and clinically significant consequence of B-cell depletion in patients with ANCA-SV, in every 5th case it is complicated by serious infections (including sepsis in 13%) and accounts for a significant proportion in the structure of lethal outcomes (31.2%).Patients treated with RTM require careful monitoring of absolute neutrophil count both during the first months after initiation of anti-B-cell therapy and thereafter. In the combined administration of RTM with cytotoxic drugs (primarily cyclophosphamide) in patients with ANCA-SV, it is necessary to consider the risk of LON developing, secondary immunodeficiency, and infectious complications. During the coronavirus pandemic, one should remember that treatment with interleukin 6 inhibitors used in severe COVID-19 can also be accompanied by neutropenia and requires careful dynamic monitoring of the absolute number of neutrophils in patients with ANCA-SV treated with RTM. It is necessary to inform both patients and physicians of the risk of LON development during the treatment of RTM in ANCA-SV and other rheumatic diseases.
- 19 June 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (3) , 37-41
Open AccessLate-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis
In the last decade, anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (SV) has been treated with the anti-B-cell drug, rituximab (RTM) both for induction and maintenance therapy. One of the problems of the treatment with RTM in patients with ANCA-SV is the risk of late-onset neutropenia (LON), mechanisms of development of which have not been studied enough yet.Objective: to evaluate the incidence and outcomes of LON in patients with ANCA-SV treated with RTM. Patients and methods. A retrospective analysis of the register of 140 patients with ANCA-SV who received RTM treatment at the V.A. Nasonova Research Institute of Rheumatology from 2009 to 2021 years. The median duration of RTM treatment was 49 (6–121) months, the median of the total RTM dose was 3.5 (0.5–9.5) grams. The duration of follow-up exceeded 6 months after the first administration of RTM.Results and discussion. LON was detected in 16 (11.4%) patients, of which 6 suffered from Wegener's granulomatosis with polyangiitis (GPA), 4 – microscopic polyangiitis (MPA), 4 – Churg-Strauss eosinophilic granulomatosis with polyangiitis (EGPA) and 2 – undifferentiated ANCA-SV. In 8 (50%) out of 16 patients, LON developed within 2 months after the 1st course of RTM, in the remaining 8 patients, on average, after 10 (4– 15.5) months. A lethal outcome was documented in 5 (31.2%) of 16 cases of LON (1 with MPA, 3 with GPA, and 1 with EGPA) on average 2 (1.5–9) months after the 1st course of RTM, at the same time, in 4 patients LON was complicated by pneumonia, including 2 with septic shock, in another 1 case LON was combined with the development of acute myocardial infarction and progression of chronic renal failure. Overall mortality among 140 patients with ANCA-SV treated with RTM was 11.4%, while in cases with a fatal outcome, the frequency of LON reached 31.2%.Conclusion. Thus, LON induced by RTM is a common (11%) and clinically significant consequence of B-cell depletion in patients with ANCA-SV, in every 5th case it is complicated by serious infections (including sepsis in 13%) and accounts for a significant proportion in the structure of lethal outcomes (31.2%).Patients treated with RTM require careful monitoring of absolute neutrophil count both during the first months after initiation of anti-B-cell therapy and thereafter. In the combined administration of RTM with cytotoxic drugs (primarily cyclophosphamide) in patients with ANCA-SV, it is necessary to consider the risk of LON developing, secondary immunodeficiency, and infectious complications. During the coronavirus pandemic, one should remember that treatment with interleukin 6 inhibitors used in severe COVID-19 can also be accompanied by neutropenia and requires careful dynamic monitoring of the absolute number of neutrophils in patients with ANCA-SV treated with RTM. It is necessary to inform both patients and physicians of the risk of LON development during the treatment of RTM in ANCA-SV and other rheumatic diseases.
- Open Access
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
On the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
Open AccessOn the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.
- Open Access
- 27 December 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (6) , 684-692
Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of AAVs, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The guideline features 26 recommendations and 5 upgraded position statements for GPA/ MPA, as well as 15 recommendations and 5 upgraded position statements for EGPA, which became the basis for the proposed algorithms for the treatment of patients with GPA/MPA and EGPA. Particular attention has been paid to the use of biologics.
- 27 December 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (6) , 684-692
Open AccessReview of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of AAVs, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The guideline features 26 recommendations and 5 upgraded position statements for GPA/ MPA, as well as 15 recommendations and 5 upgraded position statements for EGPA, which became the basis for the proposed algorithms for the treatment of patients with GPA/MPA and EGPA. Particular attention has been paid to the use of biologics.
- Open Access
- 15 July 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (3) , 357-361-361
Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
The present report illustrates efficacy of rituximab (RTX) in granulomatosis with polyangiitis (GPA) with severe lung involvement. Female patient, 45 years old, was ill since March 2016, her disease manifested at the onset with fever, recurrent epistaxis, otitis media, mastoiditis, conjunctivitis and arthritis. Thoracic CT scan showed multiple decaying pulmonary infiltrates. The presence of PR3-ANCA confirmed the diagnosis of GPA. Induction therapy included high doses of glucocorticoids, cyclophosphamide (total dose 4 g), with following azathioprine and mycophenolate mofetil. Lung disease continued to progress with emerging extensive infiltrates and forming a giant cavity with air-fluid level in the right lung. Further treatment included antibiotics followed by surgical draining of lung cavity in December 2018. Fever, necrotic rhinitis and otitis persisted despite treatment, lab findings included red blood cells in the urine, C-reactive protein 90 g/l, thrombocytosis 740×109/l, anemia (Hb 80 g/l). RTX 2 g and intravenous immunoglobulin were initiated in December 2018, a second course of RTX (0.5 g) was administered 4 months later. Patient’s condition was gradually improving, CT scan at 6 months after RTX treatment showed fibrous tissue in the area of former cavity. One year later, total RTX dose was 3.5 g, further regression of changes and GPA remission were achieved. There were no adverse reactions. Anti-B cell therapy with RTX is a safe and highly effective option in GPA patients with severe destructive lung disease, potentially curative even in cases of giant pulmonary cavities.
- 15 July 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (3) , 357-361-361
Open AccessGranulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
The present report illustrates efficacy of rituximab (RTX) in granulomatosis with polyangiitis (GPA) with severe lung involvement. Female patient, 45 years old, was ill since March 2016, her disease manifested at the onset with fever, recurrent epistaxis, otitis media, mastoiditis, conjunctivitis and arthritis. Thoracic CT scan showed multiple decaying pulmonary infiltrates. The presence of PR3-ANCA confirmed the diagnosis of GPA. Induction therapy included high doses of glucocorticoids, cyclophosphamide (total dose 4 g), with following azathioprine and mycophenolate mofetil. Lung disease continued to progress with emerging extensive infiltrates and forming a giant cavity with air-fluid level in the right lung. Further treatment included antibiotics followed by surgical draining of lung cavity in December 2018. Fever, necrotic rhinitis and otitis persisted despite treatment, lab findings included red blood cells in the urine, C-reactive protein 90 g/l, thrombocytosis 740×109/l, anemia (Hb 80 g/l). RTX 2 g and intravenous immunoglobulin were initiated in December 2018, a second course of RTX (0.5 g) was administered 4 months later. Patient’s condition was gradually improving, CT scan at 6 months after RTX treatment showed fibrous tissue in the area of former cavity. One year later, total RTX dose was 3.5 g, further regression of changes and GPA remission were achieved. There were no adverse reactions. Anti-B cell therapy with RTX is a safe and highly effective option in GPA patients with severe destructive lung disease, potentially curative even in cases of giant pulmonary cavities.
- Open Access
- 23 April 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (2) , 69-76
Avascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observation
The article provides a description of the systemic lupus erythematosus patient with multiple avascular bone necrosis (ABN), homozygous mutation in clotting factor V (Leiden) gene, who successfully underwent the total hip replacement. The role of high doses of glucocorticoids and coagulation disorders, in particular the homozygous mutation in factor V (Leiden) gene, in the development of ABN is discussed.
- 23 April 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (2) , 69-76
Open AccessAvascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observation
The article provides a description of the systemic lupus erythematosus patient with multiple avascular bone necrosis (ABN), homozygous mutation in clotting factor V (Leiden) gene, who successfully underwent the total hip replacement. The role of high doses of glucocorticoids and coagulation disorders, in particular the homozygous mutation in factor V (Leiden) gene, in the development of ABN is discussed.